AstraZeneca grants 3SBio Chinese rights to Byetta and Bydureon

13 October 2016
astrazeneca-large

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has granted Chinese biotech firm 3SBio (HKEX:1530) an exclusive license to commercialize type 2 diabetes drugs Byetta (exenatide) and the once-weekly version, Bydureon, In China.

Under the terms of the deal, 3SBio has paid AstraZeneca $50 million up front and will make milestone payments of up to $50 million.

According to 3SBio, AstraZeneca recorded $14.6 million in 2015 revenues in China for the products. Byetta, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been approved in China since 2009. 3SBio said that in May, AstraZeneca submitted a manufacturing application in China for Bydureon.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical